MGTX

+ Watchlist + Portfolio

MeiraGTx Holdings plc

Regulated industry Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $10.66
52-Week Range: $6.62 – $15.35
Market Cap: $1.04B
P/E (TTM): 12.40
EPS (TTM): 0.87
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 4.71
PEG Ratio: —
Return on Equity: 72.17%
Return on Assets: 38.65%
Gross Margin: 97.95%
Operating Margin: 76.04%
Profit Margin: 19.87%
Current Ratio: 3.76
Debt/Equity: 0.52
Total Debt: $112.32M
Free Cash Flow: $56.42M
Revenue Growth: 8608.60%
Earnings Growth: —
Enterprise Value: $1.01B

MGTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$15.92M	$14.02M	$33.28M	$81.39M
Cost of Revenue	—	$0.00	$23.79M	$4.84M
Gross Profit	—	$14.02M	$9.49M	$76.55M
Research & Development	$85.72M	$103.78M	$119.48M	$129.62M
Selling, General & Admin	$46.55M	$47.29M	$54.22M	$52.90M
Operating Expenses	$132.28M	$151.08M	$173.70M	$182.52M
Operating Income	-$116.36M	-$137.06M	-$164.21M	-$105.97M
EBITDA	-$116.07M	-$57.06M	-$121.84M	-$89.40M
Pretax Income	-$129.62M	-$84.03M	-$147.79M	-$114.20M
Net Income	-$129.62M	-$84.03M	-$147.79M	-$114.20M
Diluted EPS	-2.87	-1.49	-2.12	-1.42
Diluted Shares	45.18M	56.49M	69.82M	80.43M

MGTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$115.52M	$129.57M	$103.66M	$65.93M
Receivables	$29.02M	$23.41M	$10.63M	$18.29M
Inventory	—	$0.00	$385.00K	$0.00
Current Assets	$154.34M	$159.62M	$123.52M	$91.76M
Total Assets	$318.24M	$326.74M	$269.75M	$244.43M
Current Liabilities	$82.07M	$67.08M	$60.78M	$122.56M
Long-Term Debt	$71.03M	$72.12M	$73.22M	$49.69M
Total Debt	$92.25M	$89.26M	$84.80M	$88.69M
Total Liabilities	$200.50M	$188.57M	$201.92M	$250.22M
Retained Earnings	-$470.20M	-$554.23M	-$702.02M	-$816.22M
Shareholders' Equity	$117.74M	$138.18M	$67.83M	-$5.79M
Working Capital	$72.27M	$92.54M	$62.73M	-$30.79M
Net Debt	—	—	—	$8.41M

MGTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$73.10M	-$105.36M	-$104.50M	-$46.36M
Capital Expenditure	-$44.96M	-$20.17M	-$4.96M	-$4.24M
Free Cash Flow	-$118.06M	-$125.54M	-$109.45M	-$50.59M
Depreciation & Amortisation	$8.60M	$13.72M	$12.68M	$12.61M
Stock-Based Compensation	$28.62M	$27.72M	$25.19M	$22.11M
Investing Cash Flow	-$44.96M	$34.03M	$23.48M	-$4.11M
Financing Cash Flow	$95.20M	$84.02M	$54.53M	$12.27M
Dividends Paid	$0.00	—	—	—
Net Change in Cash	-$22.86M	$12.69M	-$26.48M	-$38.19M

MGTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.93M	$3.69M	$410.00K	$75.36M	$293.00K	$321.43M
Cost of Revenue	$1.38M	$2.68M	$313.00K	$476.00K	$198.00K	$7.16M
Gross Profit	$548.00K	$1.01M	$97.00K	$74.89M	$95.00K	$314.27M
Research & Development	$32.78M	$33.49M	$32.53M	$30.81M	$31.98M	$57.83M
Selling, General & Admin	$9.36M	$12.31M	$13.62M	$17.60M	$8.93M	$12.01M
Operating Expenses	$42.14M	$45.81M	$46.15M	$48.42M	$40.91M	$69.84M
Operating Income	-$41.60M	-$44.79M	-$46.05M	$26.47M	-$40.82M	$244.43M
EBITDA	-$33.86M	-$32.57M	-$44.29M	$21.32M	-$40.46M	$169.36M
Pretax Income	-$39.98M	-$38.80M	-$50.51M	$15.09M	-$46.31M	$163.03M
Income Tax	—	$0.00	—	—	—	$2.36M
Net Income	-$39.98M	-$38.80M	-$50.51M	$15.09M	-$46.31M	$160.72M
Diluted EPS	-0.51	-0.48	-0.62	—	-0.57	1.71
Diluted Shares	79.03M	80.59M	80.95M	—	81.30M	93.81M

MGTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$66.52M	$32.17M	$14.84M	$65.93M	$71.54M	$143.17M
Receivables	$5.22M	$6.79M	$11.81M	$18.29M	$17.96M	$44.26M
Inventory	$607.00K	$314.00K	$0.00	$0.00	—	—
Current Assets	$79.89M	$47.08M	$34.17M	$91.76M	$96.20M	$218.35M
Total Assets	$224.01M	$198.72M	$189.47M	$244.43M	$244.66M	$396.45M
Current Liabilities	$52.37M	$53.44M	$152.92M	$122.56M	$176.13M	$58.10M
Long-Term Debt	$73.50M	$73.77M	—	$49.69M	$49.70M	$100.00M
Total Debt	$80.88M	$80.47M	$88.06M	$88.69M	$87.53M	$112.32M
Total Liabilities	$190.91M	$195.76M	$230.03M	$250.22M	$302.79M	$180.67M
Retained Earnings	-$742.00M	-$780.80M	-$831.31M	-$816.22M	-$862.54M	-$701.82M
Shareholders' Equity	$33.10M	$2.96M	-$40.56M	-$5.79M	-$58.13M	$215.57M
Working Capital	$27.52M	-$6.35M	-$118.75M	-$30.79M	-$79.93M	$160.25M
Net Debt	$6.97M	$41.61M	$59.21M	$8.41M	$3.02M	—

MGTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$36.83M	-$43.95M	-$12.21M	$46.63M	$17.81M	-$38.54M
Capital Expenditure	-$1.71M	-$1.23M	-$610.00K	-$682.00K	-$2.26M	-$24.31M
Free Cash Flow	-$38.54M	-$45.18M	-$12.82M	$45.95M	$15.55M	-$62.85M
Depreciation & Amortisation	$3.08M	$3.19M	$3.16M	$3.18M	$3.01M	$2.82M
Stock-Based Compensation	$4.89M	$5.66M	$5.95M	$5.60M	$3.65M	$3.78M
Investing Cash Flow	-$1.71M	-$761.00K	-$547.00K	-$1.09M	-$2.26M	-$23.64M
Financing Cash Flow	$1.71M	$5.45M	-$219.00K	$5.33M	-$10.11M	$133.90M
Share Repurchases	$0.00	$0.00	—	—	-$18.19M	$0.00
Net Change in Cash	-$36.83M	-$39.26M	-$12.98M	$50.87M	$5.44M	$71.72M

Market Snapshot

About

MeiraGTx Holdings is a clinical-stage gene therapy company developing treatments for inherited retinal diseases, neurodegenerative disorders, and xerostomia. The company uses AAV and lentiviral vector technologies to deliver genetic therapies.